FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)        Name of exempt principal trader: Investec Bank plc
(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:
        Use a separate form for each offeror/offeree
Gooch & Housego plc
(c)        Name of the party to the offer with which exempt principal trader is connected: Investec is Advisor and Broker to Gooch & Housego plc
(d)        Date dealing undertaken: 11th September 2026

(e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?
        If it is a cash offer or possible cash offer, state “N/A”
N/A

2.        DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security Purchases/ sales

Total number of securities Highest price per unit paid/received Lowest price per unit paid/received

Ordinary shares

Sales

8,282

1207.5 1205

(b)        Cash-settled derivative transactions

Class of relevant security Product description
e.g. CFD
Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position
Number of reference securities Price per unit
N/A N/A N/A N/A N/A

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type
e.g. American, European etc.
Expiry date Option money paid/ received per unit
N/A N/A N/A N/A N/A N/A N/A N/A

(ii)        Exercise

Class of relevant security Product description
e.g. call option
Exercising/ exercised against Number of securities Exercise price per unit
N/A N/A N/A N/A N/A

(d)        Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing
e.g. subscription, conversion
Details Price per unit (if applicable)
N/A N/A N/A N/A

3.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:
(i)        the voting rights of any relevant securities under any option; or
(ii)        the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state “none”
None

Date of disclosure: 14th September 2026
Contact name: Priyali Bhattacharjee
Telephone number: +91-9923757332

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)        Name of exempt principal trader: Investec Bank plc
(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:
        Use a separate form for each offeror/offeree
Gamma Communications Plc
(c)        Name of the party to the offer with which exempt principal trader is connected: Investec is Joint Broker to Gamma Communications Plc
(d)        Date dealing undertaken: 11th September 2026

(e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?
        If it is a cash offer or possible cash offer, state “N/A”
N/A

2.        DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security Purchases/ sales

Total number of securities Highest price per unit paid/received Lowest price per unit paid/received

Ordinary shares

Purchases

295,029

1141.5 1110

Ordinary shares

Sales

295,029

1141.5 1110

(b)        Cash-settled derivative transactions

Class of relevant security Product description
e.g. CFD
Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position
Number of reference securities Price per unit
N/A N/A N/A N/A N/A

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type
e.g. American, European etc.
Expiry date Option money paid/ received per unit
N/A N/A N/A N/A N/A N/A N/A N/A

(ii)        Exercise

Class of relevant security Product description
e.g. call option
Exercising/ exercised against Number of securities Exercise price per unit
N/A N/A N/A N/A N/A

(d)        Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing
e.g. subscription, conversion
Details Price per unit (if applicable)
N/A N/A N/A N/A

3.        OTHER INFORMATION
        
(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:
(i)        the voting rights of any relevant securities under any option; or
(ii)        the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state “none”
None

Date of disclosure: 14th September 2026
Contact name: Priyali Bhattacharjee
Telephone number: +91-9923757332

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)        Name of exempt principal trader: Investec Bank Plc
(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:
        Use a separate form for each offeror/offeree
Advanced Medical Solutions Group Plc
(c)        Name of the party to the offer with which exempt principal trader is connected: Investec is Advisor & Joint Broker to Advanced Medical Solutions Group plc
(d)        Date dealing undertaken: 11th September 2026

(e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?
        If it is a cash offer or possible cash offer, state “N/A”
N/A

2.        DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security Purchases/ sales

Total number of securities Highest price per unit paid/received Lowest price per unit paid/received

Ordinary shares

Purchase

218,454

280.75 280.5

Ordinary shares

Sales

1,144,179

281 280.5

(b)        Cash-settled derivative transactions

Class of relevant security Product description
e.g. CFD
Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position
Number of reference securities Price per unit
N/A N/A N/A N/A N/A

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type
e.g. American, European etc.
Expiry date Option money paid/ received per unit
N/A N/A N/A N/A N/A N/A N/A N/A

(ii)        Exercise

Class of relevant security Product description
e.g. call option
Exercising/ exercised against Number of securities Exercise price per unit
N/A N/A N/A N/A N/A

(d)        Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing
e.g. subscription, conversion
Details Price per unit (if applicable)
N/A N/A N/A N/A

3.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:
(i)        the voting rights of any relevant securities under any option; or
(ii)        the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state “none”
None

Date of disclosure: 14th September 2026
Contact name: Priyali Bhattacharjee
Telephone number: +91-9923757332

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at ssssssswwww.thetakeoverpanel.org.uk.

Today, Novonesis will initiate the first tranche (the “First Tranche”) of the EUR 1 billion multi-year share buyback program announced in Company Announcement No. 14, on August 19, 2026. Under the First Tranche, Novonesis will acquire B shares for an aggregate amount of up to EUR 75 million, with the First Tranche expected to end no later than December 17, 2026. Based on the closing share price on September 11, 2026, the First Tranche corresponds to around 1.3 million B shares. The shares acquired under the First Tranche will be used to meet obligations arising from employee share-based incentive programs.

The maximum number of shares acquired by the company per daily market session will be equivalent to no more than 25% of the average volume of shares in the company traded on NASDAQ OMX Copenhagen during the preceding 20 business days. The share buyback program will be conducted in accordance with Article 5 of Regulation (EU) No. 596/2014 (Market Abuse Regulation) and Commission Delegated Regulation (EU) 2016/1052 (the Safe Harbour Rules).

Attachment

Bagsværd, Denmark, 14 September 2026 – Novo Nordisk marked the beginning of its next chapter today by unveiling a rebrand centred on ‘Lasting Health Starts Now’, and the single ‘Novo’ name, and by updating its culture with ‘The Novo Way’ that will enable the company to move ahead with greater focus, speed and impact. Together, the rebrand and ‘The Novo Way’ are part of how the company will deliver on its business objectives and its ambition to bring better health to many more people.

“People have always been at the centre of Novo’s science. We have transformed major areas of healthcare, such as obesity and diabetes, by bringing innovation to conditions that affect millions of lives. But the unmet need remains vast, and at the same time, people’s expectations of healthcare are changing,” said Mike Doustdar, president and CEO, Novo. “Healthcare must become more responsive, relevant and easier to fit into everyday life. Our brand and culture are strategically important and will enhance how we operate and compete, but the reason we exist will not change. We remain true to our purpose of changing people’s lives and are ambitious about our future to help them have lasting health, starting right now.”

The rebrand
‘Lasting Health Starts Now’ is at the centre of the rebrand and is based on the idea that lasting health begins today, not someday, through progress people can see and feel day by day. The rebrand will give the company a distinctive, recognisable and consistent way to connect with people, partners and other stakeholders around the world. ‘Novo’ will be used as the name of the company day-to-day, while Novo Nordisk A/S remains the legal global company name. The updated visual identity includes the Apis bull logo rooted in Novo’s heritage, while giving the brand a contemporary and future-fit expression.

The rebrand is designed to be more memorable and relevant to the way people engage with their health today. It also reflects the company’s ambition to bring breakthrough science closer to people’s daily lives and to strengthen recognition and trust as Novo reaches more people in more ways.

Corporate culture
‘The Novo Way’, introduced today, is a new set of principles that will underpin the company’s culture, building on the strengths that have defined Novo for more than a century – breakthrough science, deep expertise, care for people, and an unwavering commitment to patient safety – while setting out the behaviours and ways of working needed to innovate and lead in a faster, more competitive and increasingly consumer-driven market.

‘The Novo Way’ is built around four principles:

  1. Customer Obsession – We innovate with consumers and patients at the centre of everything we do
  2. Competitiveness – We raise our performance to create greater value for all our stakeholders
  3. Clarity – We create focus and speed through clear priorities, simple ways of working and decisive action
  4. Care & Integrity – We care for our people, show respect, and never compromise on patient safety and ethics

“Brand and culture work together: culture shapes how we reach our strategy and how we work, while brand shapes the value that people attach to our products and services, and how our company is perceived around the world,” said Tania Sabroe, executive vice president, People, Organisation & Corporate Affairs, Novo. “Our updated culture will enable us to move with focus and speed, and our rebrand ensures we show up with relevance and distinctiveness across medicines, partnerships, marketing and stakeholder engagement. Together, these will sharpen our competitive edge and strengthen our role as a trusted partner in healthcare.”

At its Capital Markets Day on 21 September in London, Novo will provide a detailed overview of the updated corporate strategy. Details can be found on the Investor Relations page of novonordisk.com.

To see more of the new Novo brand elements and the Novo Way, go to novonordisk.com.

Novo is the global healthcare company that believes lasting health starts now. For over a century, we’ve combined leading scientific expertise with a deep understanding of people’s lives. We develop treatments and support that help millions of people make progress they can see, feel and sustain now and in the future. Every day, over 67,000 employees around the world advance our purpose to drive change for lasting health. Through our partnerships, programmes and investments, we’re working to prevent disease, expand access to treatments and reduce our environmental impact to help even more people live healthier lives. For more information, visit novonordisk.com and follow us on Instagram, LinkedIn, TikTok, Facebook, X and YouTube. 

Contacts for further information

Novo Nordisk Media:  
Ambre James-Brown
+45 3079 9289
globalmedia@novonordisk.com

Liz Skrbkova (US)
+1 609 917 0632
USMediaRelations@novonordisk.com

Novo Nordisk Investors:  
Michael Novod
+45 3075 6050
nvno@novonordisk.com

Sina Meyer
+45 3079 6656
azey@novonordisk.com

Christoffer Togo Solgaard-Tullin
+45 3079 1471
cftu@novonordisk.com

 
Ida Schaap Melvold
+45 3077 5649
idmg@novonordisk.com

Mads Berner Bruun
+45 3075 2936
mbbz@novonordisk.com

Frederik Taylor Pitter (US)
+1 609 613 0568
fptr@novonordisk.com

Alex Bruce (US)
+1 640 230 0276
axeu@novonordisk.com

Attachment

VANCOUVER, British Columbia, Sept. 14, 2026 (GLOBE NEWSWIRE) — Li-FT Power Ltd. (“LIFT” or the “Company”) (TSXV: LIFT) (ASX: LFT) (OTCQX: LIFFF) (Frankfurt: WS0) is pleased to announce that the Company’s Yellowknife Lithium Project and Lithium Carbonate Conversion Facility has been selected for inclusion in the investment prospectus for the Canada Investment Summit, taking place September 14-15, 2026, in Toronto.

Hosted by Prime Minister Mark Carney in partnership with CPP Investments and PSP Investments, the Canada Investment Summit will convene leading global investors, Canadian business leaders and government representatives to connect capital with Canadian investment opportunities, advance major projects, and mobilise long-term investment in sectors of strategic importance to Canada, including critical minerals.

“LIFT is proud to be included in the Canada Investment Summit alongside some of the country’s most significant investment opportunities” said Francis MacDonald, CEO of Li-FT Power. “We have scale in the ground and a strategy to extend that value downstream, combining large lithium resources at the Yellowknife and Adina-Galinée projects with the potential for battery-grade lithium carbonate conversion in Canada to strengthen North American supply chain security. The Summit provides an important opportunity to engage directly with global investors and strategic partners as we advance our projects and build the partnerships required to move them forward.”

LIFT is building a large-scale Canadian lithium platform spanning the Yellowknife and Adina-Galinée projects, with a strategy to extend upstream lithium development downstream into battery-grade lithium carbonate production (Figure 1). The Company’s integrated development strategy is designed to capture more value in Canada while strengthening North American lithium supply chain security.

Figure 1

Figure 1 – LIFT’s hard-rock lithium portfolio.

Investor Relations Engagement

LIFT is pleased to announce that it has entered into a consulting agreement with Prospect Capital Relations effective September 15, 2026 (the “Consulting Agreement”) to provide investor relations services to the Company, including coordinating contacts with the investment community and responding to shareholder inquiries on the recent developments within the Company. In addition, Prospect Capital Relations will organize and attend roadshows in conjunction with the organization of conferences.

Under the terms of the Consulting Agreement, the Company will pay Prospect Capital Relations a fee of C$10,500 per month plus applicable taxes. Either party may terminate the Consulting Agreement on 30 days’ prior written notice. The Consulting Agreement is subject to the approval of the TSX Venture Exchange.

Prospect Capital Relations is owned by John David MacDougall and is an arm’s length party to the Company. To the Company’s knowledge, as of the date of this news release, Mr. MacDougall beneficially owns a nominal number of common shares of the Company.

For further information, please contact:

Francis MacDonald        
Chief Executive Officer        
Tel: + 1.604.609.6185        
Email: investors@li-ft.com         
Website: www.li-ft.com

This release is authorised by the Board of Directors of Li-FT Power Ltd.

About LIFT

LIFT is focused on developing a portfolio of hard rock lithium assets in Canada, with core development assets in both Québec and the Northwest Territories. The Company owns the Adina-Galinée Lithium Project in the Eeyou Istchee James Bay region of Québec and the Yellowknife Lithium Project in the Northwest Territories. LIFT also holds early-stage exploration properties in both jurisdictions.

Cautionary Statement Regarding Forward-Looking Information

Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward-looking statements. These forward-looking statements and information reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company with respect to the matter described in this news release.

Forward-looking statements involve risks and uncertainties, which are based on current expectations as of the date of this release and subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Additional information about these assumptions and risks and uncertainties is contained under “Risk Factors” in the Company’s latest annual information form filed on April 27, 2026, which is available under the Company’s SEDAR+ profile at www.sedarplus.ca, in the Company’s prospectus supplement dated August 6, 2026 and in other filings that the Company has made and may make with applicable securities authorities in the future. Forward-looking statements contained herein are made only as to the date of this press release and we undertake no obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/4c987287-031d-4ddf-8289-e25b0313ae0b

Press Release
ESpanix deploys Nokia Deepfield Defender to protect Spain’s internet traffic from DDoS attacks 

  • Spain’s largest internet exchange point deploys Nokia’s AI-driven DDoS security to detect and mitigate attacks that cross its Barcelona- and Madrid-based exchange platform within seconds.
  • A new optional DDoS protection service is available to more than 200 national and international networks connected to ESpanix, which together serve the majority of internet end users in Spain.
  • In-network protection keeps Spanish internet traffic — and its security — inside Spain, supporting data sovereignty and European regulatory expectations.

14 September, 2026

Espoo, Finland – Nokia today announced that ESpanix, Spain’s largest internet exchange point (IXP), has selected and deployed Nokia Deepfield Defender to protect its exchange platform and connected networks against distributed denial-of-service (DDoS) attacks. The deployment enables ESpanix to offer DDoS protection as a new, optional value-added service to the more than 200 national and international networks that exchange traffic at the ESpanix Node and together serve the vast majority of internet end users in Spain.

DDoS attacks continue to grow in size, frequency, and sophistication, with massive botnets of compromised IoT devices and weaponized residential proxies driving hyper-volumetric and application-layer attacks against networks, services, and end users. As the central crossroads of the Spanish internet, the ESpanix Node occupies a strategic position: stopping attack traffic at the exchange prevents it from ever reaching the networks — and the businesses, public services, and consumers — behind its ports.

“DDoS attacks remain a primary threat to our connected networks daily. Integrating a proactive detection and mitigation solution into our infrastructure represents a significant step forward in ESpanix’s ongoing commitment to maximizing security across our service portfolio. Leveraging the exceptional detection granularity of Nokia Deepfield, we can substantially reduce the impact of DDoS events by isolating and removing only unwanted traffic. Crucially, this protection is delivered entirely within our network and within Spain, across the six datacentres in Madrid and Barcelona where we connect with our members. This ensures that local traffic remains local, eliminating any need for detours through third-party scrubbing infrastructure and thereby guaranteeing strict data sovereignty. By unifying these capabilities, we have made DDoS protection far simpler to implement and operate, ensuring that our end users need no specific technical expertise to enjoy robust, seamless defense. This new service enhances the value of connecting to the ESpanix Node and introduces a new dimension to the services we offer our members,” said Javier Achirica, CTO, ESpanix.

“Internet exchanges are critical infrastructure — and for Spain, ESpanix is where the national internet comes together, which also makes it the smartest place to stop DDoS attacks. With Deepfield Defender, ESpanix detects and removes attack traffic in seconds, directly in the network and inside the country. This deployment shows how internet exchanges across Europe can turn security into stronger resilience for their members and a new source of value at the same time,” said Jeff Smith, Vice President and General Manager, Nokia Deepfield.

Nokia Deepfield Defender combines AI-driven, big data analytics of network telemetry with Deepfield Secure Genome®, Nokia’s proprietary, cloud-based data feed that tracks the security context of the internet. Defender detects all types of DDoS attacks in seconds and drives automated, network-based mitigation with a very high degree of granularity — surgically removing only unwanted traffic while legitimate packets keep flowing. By unifying detection and mitigation in the network itself, ESpanix avoids rerouting member traffic to external scrubbing centers: attacks are identified and removed where the traffic flows, keeping Spanish internet traffic and the responsibility for securing it within Spain.

The deployment extends a partnership that, in 2025, made ESpanix the first IXP in Spain to offer 400G connectivity to its customers, built on Nokia interconnect and service routers running over Nokia optical transport. With Deepfield Defender, ESpanix joins a growing group of leading European internet exchanges that use Nokia Deepfield to protect their members and to build new security services on top of their interconnection platforms. For exchanges, the deployment model has a multiplier effect: a single deployment at an exchange extends protection to every network that connects through it.

The new DDoS protection service is being introduced to the ESpanix community and the wider industry at upcoming events.

Multimedia, technical information and related news

About Nokia
Nokia is the world’s leading provider of network technology and enables a new era of artificial intelligence. We are developing the networks of the future that connect people, devices and intelligence. Our network solutions span fixed and mobile networks, as well as IP, optical, core, and data center networks. Our secure, AI-native network infrastructure enables the application and utilization of AI on a global scale.

About ESpanix

ESpanix is one of the largest Digital Hubs in Southern Europe and the oldest one in Spain. The company operates across three business areas: interconnection, data centers and value-added services. ESpanix services are available in the Calle Mesena building in Madrid as well as in five POPs within the metropolitan areas of Barcelona and Madrid. ESpanix Datacentre is a Tier IV compliant building and allows for direct connection with all the major national and international fiber and capacity providers. The majority of Spanish ISPs are connected to ESpanix Node. “Si pasa en Internet, pasa por ESpanix”

Media inquiries
Nokia Press Office
Email: Press.Services@nokia.com

ESpanix Press Office
Email: press@espanix.net

Follow us on social media
LinkedIn X Instagram Facebook YouTube

On 12 May 2026, Gabriel Holding A/S initiated a share buy-back programme. The buy-back runs from 12 May 2026 up to and including 16 March 2027. During this period, Gabriel Holding A/S may repurchase up to 94,500 shares corresponding to 5% of the share capital.

Gabriel Holding A/S held 55,109 treasury shares at the start of the share buyback programme.

The buy-back is executed in accordance with Article 5 of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour Regulation. The buy-back is carried out on Nasdaq Copenhagen at market price and in accordance with the authorization granted by the general meeting, Nasdaq Copenhagen’s rules for issuers, as well as Gabriel Holding A/S’ internal rules on insider matters and handling of inside information.

The following transactions have been carried out under the programme during the period below:

  Number of shares Average purchase price Transaction value in DKK
Treasury shares before start of programme 55.109    
Accumulated under the programme in accordance with the latest announcement 6,650 272.28 1,810,644
Monday, 7 September 2026 65 232.00 15,080
Tuesday, 8 September 2026 65 226.46 14,720
Wednesday, 9 September 2026 75 235.73 17,680
Thursday, 10 September 2026 80 231.50 18,520
Friday, 11 September 2026 80 228.50 18,280
Accumulated under the programme in accordance with the above transactions 7,015 270.12 1,894,924

With the above transactions, the company’s holding of treasury shares amounts to 62,124 shares, corresponding to 3.29% of the total number of issued shares of 1,890,000.

Inquiries and further information:
CEO Anders Hedegaard Petersen, phone +45 9630 3117

Appendix

Detailed data on share buy-back transactions is enclosed in accordance with Commission Delegated Regulation (EU) 2016/1052 supplementing Regulation (EU) No. 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the conditions applicable to buy-back programmes and stabilisation measures, Article 2. All transactions have been carried out by Danske Bank A/S on behalf of Gabriel Holding A/S.

Volume Price Venue Time – GMT Time – CET
35 232 XCSE 20260907 11:01:58.180872 +0100s 20260907 12:01:58.180872
30 232 XCSE 20260907 15:17:01.936078 +0100s 20260907 16:17:01.936078
10 226 XCSE 20260908 11:46:55.888102 +0100s 20260908 12:46:55.888102
40 226 XCSE 20260908 11:46:55.888102 +0100s 20260908 12:46:55.888102
15 228 XCSE 20260908 14:44:44.864907 +0100s 20260908 15:44:44.864907
20 236 XCSE 20260909 08:06:50.075971 +0100s 20260909 9:06:50.075971
15 236 XCSE 20260909 08:26:25.473327 +0100s 20260909 9:26:25.473327
10 234 XCSE 20260909 08:33:46.476233 +0100s 20260909 9:33:46.476233
20 236 XCSE 20260909 12:34:11.410570 +0100s 20260909 13:34:11.410570
10 236 XCSE 20260909 13:01:13.922775 +0100s 20260909 14:01:13.922775
20 230 XCSE 20260910 10:18:03.854284 +0100s 20260910 11:18:03.854284
40 232 XCSE 20260910 12:07:32.792097 +0100s 20260910 13:07:32.792097
20 232 XCSE 20260910 13:49:56.646424 +0100s 20260910 14:49:56.646424
40 230 XCSE 20260911 08:54:10.629286 +0100s 20260911 9:54:10.629286
20 226 XCSE 20260911 11:37:27.065596 +0100s 20260911 12:37:27.065596
20 228 XCSE 20260911 15:38:56.560102 +0100s 20260911 16:38:56.560102

This is a translation of the original Danish text. In the event of discrepancies between the Danish and English texts, the Danish version shall prevail.

Attachment

  • Cellectis to advance two lead in vivo programs .HEAL-101 and .HEAL-201 in severe dyslipidemias with preliminary Phase 1 data planned in H2 2027 and H1 2028, respectively
  • Transformation supported by continuing existing cell therapy partnerships while exiting lasme-cel and eti-cel development
  • Realignment of the operating model targeting Cellectis cash runway extension into H2 2028
  • Conference call and webcast on September 14: English at 8 a.m. ET, French at 9 a.m. ET

NEW YORK, Sept. 14, 2026 (GLOBE NEWSWIRE) — Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a pioneer in gene editing, announced that on September 11, 2026, the board of directors approved a strategic transformation to become an in vivo gene editing company focused on developing long-lasting treatments for chronic diseases.

A differentiated in vivo Gene Editing pipeline

The Company’s strategic transformation builds on the achievement of promising preclinical proof-of-concept for its lead candidate programs, .HEAL-101 and .HEAL-201. .HEAL-101 is an in vivo base editing product candidate targeting APOC3 for severe hypertriglyceridemia and .HEAL-201 is an in vivo epigenetic editing product candidate targeting PCSK9 for severe hypercholesterolemia.

.HEAL-101

  • Severe hypertriglyceridemia (sHTG) remains a significant unmet medical need, with affected patients facing a high risk of acute pancreatitis, an increased burden of cardiovascular disease, and limited treatment options. .HEAL-101 is being developed for patients with high-risk sHTG, including those with triglyceride levels ≥880 mg/dL or ≥500 mg/dL with a history of acute pancreatitis, representing an estimated target population of approximately 1 to 2 million patients across the United States and Europe.
  • .HEAL-101 targets the human APOC3 gene, a well-validated target for sHTG, via a TALE-base editor specific to the APOC3 gene (“APOC3 TALEB”) formulated in Lipid Nanoparticles (LNP).
  • The APOC3 TALEB displayed high on-site base editing activity when transfected as mRNA in a hepatic cell line (mean base editing >70%) and base editing translated into a deep and significant reduction of APOC3 protein secretion (mean reduction >70%). APOC3 TALEB displayed a highly specific base editing profile using an unbiased, genome wide off-site identification method.
  • Intravenous injection of .HEAL-101 in a liver humanized normolipidemic murine model successfully edited human APOC3 (mean on-site base editing ~55%) and decreased plasmatic APOC3 levels (mean decrease ~60%; up to 70%), associated with a decrease of circulating triglycerides (mean decrease ~45%; up to 68% with respect to pre-treatment baseline). It did not significantly increase the level of liver ALT (alanine aminotransferase) compared to untreated control.
  • Intravenous injection of .HEAL-101 in a hypertriglyceridemic humanized APOC3 transgenic murine model significantly decreased plasmatic APOC3 levels (mean decrease ~70%) and triglyceride levels (means decrease ~76%) compared to pre-treatment baseline, demonstrating the efficacy of .HEAL-101 in a relevant disease model.
  • The Company plans to initiate a Phase 1 investigator-initiated trial (IIT) in China and share the preliminary clinical data from this program in H2 2027.

.HEAL-201

  • Severe hypercholesterolemia remains a major driver of atherosclerotic cardiovascular disease, with many high-risk patients continuing to experience elevated low-density lipoprotein cholesterol (LDL-C) levels despite currently available therapies. This burden is particularly significant among younger high-risk patients with severe genetic forms of hypercholesterolemia and those with premature cardiovascular disease, representing an estimated 1 to 2 million patients across the United States and Europe. .HEAL-201 is being developed to address the needs of these high-risk patient populations.
  • .HEAL-201 targets the human PCSK9 gene, a well-validated target for severe hypercholesterolemia, via a TALE-epigenetic modulator specific to the promoter of PCSK9 (“PCSK9 TALEM”) formulated in LNP to treat severe hypercholesterolemia.
  • The PCSK9 TALEM displayed a high on-site epigenome editing activity when transfected as mRNA in a hepatic cell line (mean base editing >90%). Epigenome editing translates into a stable, deep and significant reduction of PCSK9 transcript levels and PCSK9 secretion without evidence for off-site gene and protein modulation.
  • Intravenous injection of PCSK9 TALEM mRNA LNPs in a liver humanized murine model, successfully decreased plasmatic levels of PCSK9 (mean >90%).
  • The Company plans to initiate a Phase 1 IIT in China and share the preliminary clinical data from this program in H1 2028.

Cellectis’ differentiated gene editing platform

Cellectis’ core competencies encompass nuclease editing, base editing, epigenetic editing and transcriptional regulation. While most gene editing companies focus on a single editing modality, Cellectis’ broad gene editing toolbox built over a quarter century allows for a combination of therapeutic targets utilizing several gene editing modalities.

André Choulika, Ph.D., Co-Founder and Chief Executive Officer of Cellectis, commented: “Gene surgery has the potential to transform the treatment of high-risk metabolic diseases by delivering long-lasting benefits through a single IV injection. Our decision to focus Cellectis on in vivo Gene Editing reflects the progress we have made with .HEAL-101 and .HEAL-201 and our assessment of where our gene editing capabilities can be most effectively deployed. These programs use two distinct approaches from our platform, base editing of APOC3 and epigenetic editing of PCSK9, which are designed to provide highly specific genomic or epigenomic modulation with the goal of avoiding double-strand DNA breaks. They have generated encouraging preclinical proof-of-concept and our priority is now to advance both programs toward the clinic and generate first-in-human data.”

Lasme-cel and eti-cel

In 2026, despite our continued conviction in the promise of allogeneic CAR T-cell therapies and strong physician interest in lasme-cel and eti-cel, the commercial and clinical landscape for B-ALL and NHL changed materially. Continued and recently accelerated advances in frontline treatment regimens have lowered relapse rates, reducing the number of patients progressing to later lines of therapy. Concurrently, the rapid emergence of bispecific antibodies and in vivo CAR-T approaches has intensified competition in second and third-line treatment settings. Together, these dynamics have reduced the addressable patient population for lasme-cel and eti-cel, resulting in slower enrollment, a potentially longer and more costly development pathway, and therefore a delayed timeline to potential registration. We believe these trends are likely to continue and further constrain the commercial opportunity for both product candidates.

After a thorough assessment of the evolving therapeutic landscape and strategic review, the Company has determined that the most effective use of its financial and operational resources is to focus on and accelerate the advancement of its most promising in vivo gene editing assets. Cellectis will therefore exit the development of lasme-cel and eti-cel, while seeking strategic partnering opportunities to maximize their value.

Operational realignment to the new strategic direction

The Company will realign its organization1 and resources to focus on its in vivo Gene Editing pipeline and support its existing cell therapy partnerships with AstraZeneca, Allogene, Servier and Iovance. These combined actions are being designed to extend the Company’s cash runway into H2 20282, providing financial flexibility to advance Cellectis’ in vivo Gene Editing pipeline through key development milestones.

Conference Call

The Cellectis management team will host a conference call and webcast on September 14, 2026:

A replay will be available on the Company’s website, under the Investors section “Events & Webcasts” following the event.

In this context, the trading of Cellectis’ ordinary shares on the regulated market of Euronext Growth market of Euronext Paris will be temporarily halted, at the Company’s request, on Monday September 14, 2026 from the opening of the market at 9:00 a.m. CET until the opening of the Nasdaq Global Market at 3:30 p.m. CET.

About Cellectis

Cellectis is a genome engineering company developing genetic medicines for diseases that today demand a lifetime of treatment. Leveraging decades of expertise in programmable DNA-binding proteins, the Company has built a differentiated genome engineering platform spanning gene editing, base editing, epigenetic editing and transcriptional regulation. By delivering the genomic intervention each disease requires, Cellectis is advancing a new generation of genetic medicines designed to move beyond disease management and toward lasting therapeutic impact.

Cellectis’ headquarters are in Paris, France, with locations in New York, and Raleigh (NC). Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more, visit www.cellectis.com and follow Cellectis on LinkedIn and X.

Cautionary Statement

This press release contains “forward-looking” statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as “believe,” “can,” “design”, “encouraging,” “expect”, “into”, “moving forward”, “plan”, “potential”, “promising,” “target”, “will”, or similar expressions and/or the negative of these. These forward-looking statements are based on our management’s current expectations and assumptions and on information currently available to management. Forward-looking statements in this press release include statements regarding the Company’s transition into an in vivo gene editing company, the ability of the Company to initiate a IIT in China, the planned timing for the release of first-in-human data for the Company’s lead programs, the potential for success of the Company’s in vivo gene editing programs, the ability to continue advancement of cell therapy activities through existing partnerships, the ability to partner lasme-cel and/or eti-cel, the anticipated impact, including potential cost savings, of the Company’s decision to cease the development of lasme-cel and eti-cel and to initiate a restructuring plan, the contemplated implementation of headcount reductions and other cost-savings initiatives and their planned timeframe, and the targeted extension of the Company’s cash runway. Actual results, performance or events may differ materially from those projected in any forward-looking statement. Many important factors may adversely affect such forward-looking statements and cause actual results to differ from those in any forward-looking statement, including, without limitation, uncertainties inherent in the initiation and completion of preclinical and clinical studies; the availability and timing of results from studies, once initiated; the acceptance by global regulatory agencies of data generated from IIT in China; the potential that pre-clinical animal model data may not translate into further preclinical development or clinical setting; promising preclinical data not yielding positive further preclinical data or clinical results; the performance of the IIT in China, changes in the competitive landscape for in vivo gene editing products; expectations for regulatory approvals to conduct clinical trials; availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements; and impacts of the Company’s headcount reductions and other cost savings initiatives, which may include operational and strategic challenges. With respect to our cash runway, our operating plans, including product development plans, may change as a result of various factors, including factors currently unknown to us. Furthermore, many other important factors, including those described in our Annual Report on Form 20-F as amended and in our annual financial report (including the management report) for the year ended December 31, 2025 and subsequent filings Cellectis makes with the Securities Exchange Commission from time to time, which are available on the SEC’s website at www.sec.gov, as well as other known and unknown risks and uncertainties may adversely affect such forward-looking statements and cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

For further information on Cellectis, please contact:

Media contacts:              
Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33, media@cellectis.com        
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93      

Investor Relations contact:
Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com

_____________________________
1 Subject to the completion of the relevant works council consultation process and applicable US & French labor law requirements.

2 Excluding any impact from the potential future partnering of lasme-cel and/or eti-cel.

Attachment

COPENHAGEN, Denmark, September 14, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on September 1, 2026, under which the Company will repurchase shares for an amount up to DKK 250 million in the period from September 1, 2026 to October 30, 2026. The program is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052, which together constitute the Safe Harbour Regulation.

Since the last announcement of transactions on September 7, 2026, the following transactions have been made by Nordea on behalf of Bavarian Nordic:

  Number of shares Average purchase price, DKK Transaction value, DKK
Accumulated until September 7, 2026 132,715 219.26 29,099,679
September 7, 2026  48,000 211.67  10,159,992
September 8, 2026  24,210 210.13  5,087,315
September 9, 2026  60,000 203.63  12,217,968
September 10, 2026  10,000 203.32  2,033,170
September 11, 2026  8,510 203.64  1,732,937
Accumulated under the program 283,435 212.86 60,331,061

The details for each transaction made under the share repurchase program are published on bavarian-nordic.com.

Following these transactions, Bavarian Nordic holds a total of 3,842,026 treasury shares, corresponding to 4.85% of the Company’s share capital.

About Bavarian Nordic
Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit www.bavarian-nordic.com

Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Contact investors:
Anders Hjort, Head of Investor Relations, ahjo@bavarian-nordic.com, Tel: +45 44 74 99 58
Graham Morrell, Gilmartin Group, graham@gilmartinir.com, Tel: +1 781 686 9600

Contact media:
Isabel Hagbrink, Head of Media Relations, isha@bavarian-nordic.com, Tel: +45 71 79 67 33

Company Announcement no. 42 / 2026

Attachments

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.